Yeomans Consulting Group Inc. Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Yeomans Consulting Group Inc. purchased a new position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,802 shares of the company’s stock, valued at approximately $241,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. NBC Securities Inc. bought a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at approximately $34,000. Vermillion Wealth Management Inc. purchased a new stake in Verona Pharma PLC American Depositary Share in the fourth quarter worth $46,000. GF Fund Management CO. LTD. bought a new position in shares of Verona Pharma PLC American Depositary Share during the 4th quarter worth $72,000. Avanza Fonder AB bought a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter worth $100,000. Finally, GAMMA Investing LLC grew its position in shares of Verona Pharma PLC American Depositary Share by 14.0% during the 1st quarter. GAMMA Investing LLC now owns 1,837 shares of the company’s stock worth $117,000 after buying an additional 225 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

Insider Transactions at Verona Pharma PLC American Depositary Share

In other news, CFO Mark W. Hahn sold 400,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total value of $4,560,000.00. Following the transaction, the chief financial officer owned 12,278,992 shares of the company’s stock, valued at approximately $139,980,508.80. The trade was a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Andrew Fisher sold 80,000 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $11.53, for a total value of $922,400.00. Following the completion of the transaction, the general counsel directly owned 359,999 shares in the company, valued at approximately $4,150,788.47. The trade was a 18.18% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,965,800 shares of company stock worth $20,056,881. 4.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Roth Capital downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Cowen downgraded Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Wednesday, July 9th. TD Cowen downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Truist Financial downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Finally, Canaccord Genuity Group downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price target for the company. in a report on Wednesday, July 9th. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Verona Pharma PLC American Depositary Share has a consensus rating of “Hold” and a consensus price target of $109.00.

Verona Pharma PLC American Depositary Share Trading Up 0.1%

Verona Pharma PLC American Depositary Share stock traded up $0.07 during midday trading on Friday, reaching $104.85. 638,213 shares of the stock traded hands, compared to its average volume of 1,714,766. The company has a 50-day simple moving average of $86.72 and a two-hundred day simple moving average of $69.28. Verona Pharma PLC American Depositary Share has a 12-month low of $18.51 and a 12-month high of $104.99. The firm has a market cap of $8.93 billion, a PE ratio of -52.42 and a beta of 0.24. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to analysts’ expectations of $41.47 million. Research analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.